Sanofi earnings, Revenue beat in Q3
Investing.com - Sanofi (PA:SASY) reported on Thursday third quarter {{erl-414||earnings that beat analysts' forecasts and revenue that topped expectations. Sanofi announced earnings per...
Buy
or
Sanofi News & Analysis
-
-
2 Pharma Stocks To Buy As Recommended By ICICI Direct For 12 Months
There has been seen correction in the markets amid weak global cues and Nifty has drifted from highs of 18600 to levels of 18056 levels, a 3 percent correction. The current correction is...
-
Sanofi EPS beats by €0.19, revenue in-line, boost FY outlook
Sanofi (SNY): Q3 Non-GAAP EPS of €2.18 beats by €0.19; GAAP EPS of €1.85.Revenue of €10.43B in-line.Press ReleaseQ3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to...
-
DelveInsight Analyzes a Thriving Cutaneous Lupus Erythematosus Pipeline in the Coming Years as Key Pharma Companies Enter the Sphere
Las Vegas, USA, Oct. 27, 2021 (GLOBE NEWSWIRE) -- DelveInsight Analyzes a Thriving Cutaneous Lupus Erythematosus Pipeline in the Coming Years as Key Pharma Companies Enter the Sphere The...
-
Sanofi Q3 2021 Earnings Preview
Sanofi (NASDAQ:SNY) is scheduled to announce Q3 earnings results on Thursday, October 28th, before market open.The consensus EPS Estimate is €1.98 and the consensus Revenue...
-
Sanofi India appoints Radhika Shah as Company Secretary and KMP; Stock climbs over 2%
Radhika Shah will also be the Compliance Officer with effect from November 01, 2021 in place of Vaibhav Karandikar.
-
Sanofi India gains after Q3 PAT soars to Rs 530 cr
Sanofi India rose 1.08% to Rs 8,179 after the company's standalone net profit surged 298.64% to Rs 529.80 crore on a 9.88% rise in revenue from operations to Rs 754.50 crore in Q3 September...
-
Sanofi India gains after Q3 September PAT grows 4-fold to Rs 530 cr
Sanofi India rose 1.08% to Rs 8,179 after the company's standalone net profit surged 298.64% to Rs 529.80 crore on a 9.88% rise in revenue from operations to Rs 754.50 crore in Q3 September...
-
Sanofi India Q3 results: Co posts net profit at Rs 530 crore
Sanofi India board in its meeting held on July 27 had approved a transaction for slump sale and transfer of its nutraceuticals business to Universal Nutriscience for a consideration of Rs...
-
Sanofi India net profit at Rs 530 crore in September quarter
The company's revenue from operations rose to Rs 754.5 crore as compared to Rs 686.6 crore in the year-ago period
-
Sanofi India standalone net profit rises 298.65% in the September 2021 quarter
Sales rise 9.89% to Rs 754.50 crore
-
Sanofi's Dupixent could generate over EUR 1B in sales from new indication - BofA
On Monday, Sanofi (SNY) and partner Regeneron (REGN) announced positive topline data from a late-stage trial for Dupixent (dupilumab) in patients aged 12 years and above with...
-
Kadmon gains after announcing expiry of HSR waiting period for Sanofi deal
Sanofi (SNY) has got one step closer to complete its acquisition of Kadmon Holdings
-
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
Here's a roundup of top ... Full story available on Benzinga.com
-
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news. Moderna, Inc....
-
Propulsion of Malignant Mesothelioma Pipeline as Novel and Extensive Therapies Enter the Treatment Domain, Anticipates DelveInsight
Las Vegas, USA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Propulsion of Malignant Mesothelioma Pipeline as Novel and Extensive Therapies Enter the Treatment Domain, Anticipates...
-
New toxic drug impurities detected in some heart pills in US
The impurities were found in blood pressure drugs which have been recalled in Canada as well as Europe earlier this year. U.S. officials helped lead the way in the 2018 recalls of the same...
-
Health Canada approves Sanofi's Sarclisa combination for multiple myeloma
Sanofi Canada (SNY) announces that Health Canada has approved SARCLISA in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed...
-
Sanofi's tolebrutinib shows promising action in Phase 2b multiple sclerosis study
Sanofi’s (SNY) tolebrutinib demonstrated favorable one-year tolerability in a Phase 2b long-term extension study ((LTS)) in patients with relapsing forms of multiple sclerosis...
-
Sanofi expects constraints for Kevzara supplies until early 2022
Sanofi says that there could be supply constraints for the company’s rheumatoid arthritis drug sarilumab (Kevzara) until early 2022 due to COVID-19 driven demand for Interleukin...
-
Vaccines for malaria and dengue may hit Indian market in 2-4 years
There are several candidates in the works - the Serum Institute of India, Bharat Biotech, and Zydus Cadila are working on either developing or manufacturing anti-malarial vaccines
-
Giving Moderna's COVID-19 booster at the same time as Sanofi's flu is safe and effective
U.S.-listed shares of Sanofi gained 0.4% in trading on Friday after it announced that co-administering a flu shot with Moderna Inc.'s experimental COVID-19 booster in seniors is safe and...
-
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in ... Full story available on Benzinga.com
-
Mirati to work with Sanofi on combination candidate for non-small cell lung cancer
Mirati Therapeutics will collaborate with Sanofi on a combination of adagrasib, Mirati's KRAS inhibitor, and the latter's SHP2 inhibitor, SAR442720 (RMC-4630), for NSCLC.
-
Study: Co-administration of Sanofi high-dose flu shot and Moderna COVID vaccine is OK
Administering Sanofi's Fluzone high-dose flu shot at the same time as a booster dose of Moderna's COVID-19 vaccine leads to similar immunogenicity responses.
-
Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)
eIF2B activator DNL343 achieved safety and biomarker goals in a Phase 1 study in healthy volunteers; a Phase 1b study began in individuals with ALS in Q3 2021 Fast Track designation granted...
-
: Allowing people to mix COVID-19 vaccines could cut into Pfizer and Moderna’s revenue next year
Expect to see data this month from several clinical trials that are trying to establish if “mixing and matching” different COVID-19 vaccines is safe and effective or if it’s better to get...
-
Sanofi says mid-stage trial for atopic dermatitis therapy met primary endpoints
Announcing results from a Phase 2a study for its atopic dermatitis therapy amlitelimab, Sanofi (SNY) said that the experimental therapy at a lower dose achieved a better efficacy...
-
Sanofi receives consideration of Rs 587.64 cr for sale of its nutraceuticals biz
On 29 September 2021
-
Sanofi drops plans for messenger RNA vaccine against coronavirus
French drugmaker Sanofi said Tuesday it was shelving plans for a Covid-19 vaccine based on messenger RNA despite positive results from early stage testing
-
Coronavirus Update: Hopes rise for FDA OK of vaccination for kids as young as 5
Coronavirus Update: Hopes rise for FDA OK of vaccination for kids as young as 5
-
Powell in Congress, Energy Crisis, Rotation Trades - What's Moving Markets
By Geoffrey Smith Investing.com -- Federal Reserve Chair Jerome Powell will field questions on the economy, the debt ceiling and the trading activities of his subordinates when he testifies...
-
Coronavirus Update: Hopes rise that Pfizer COVID-19 vaccine will be authorized for use in children aged 5 to 11 by late October, and Russia suffers worst one-day death toll
Pfizer and German partner BioNTech have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, raising...
-
Sanofi ends a Covid-19 vaccine effort, saying market is already well served
Despite promising trial data, French pharmaceutical giant says it doesn’t see a market for new vaccine entrants
-
Vaccines Market Worth $112.9 Billion by 2028 – Exclusive Report by Meticulous Research®
Redding, California, Sept. 28, 2021 (GLOBE NEWSWIRE) -- According to a new market research report, "Vaccines Market By Indication (Influenza, Rotavirus, DTP Vaccines), Route of...
-
Sanofi drops plans for messenger RNA vaccine against virus
The Paris-based company said it will continue to develop another vaccine candidate that is already undergoing late stage human trials. That vaccine, developed jointly with Britain's...
-
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (NASDAQ: XLRN)...
-
Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know
Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi says that the market...
-
Sanofi drops developmental plans for mRNA COVID-19 vaccine, targets other pathogens
Despite announcing positive Phase 1/2 study interim results, Sanofi (SNY) is abandoning plans for its own mRNA-based COVID-19 vaccine and will shift focus to pursue vaccines for...
-
Pharmaceutical giant Sanofi ends development of Covid messenger-RNA vaccine
The pharmaceutical giant, which has lagged rivals in deploying technology behind some of the world's top-selling Covid shots, made the decision despite positive results in phase one and two...
-
Sanofi ditches mRNA coronavirus vaccine amid rivals' success
German biotech firm CureVac earlier this month also acknowledged rivals' dominance
-
Sanofi Ends a Covid-19 Vaccine Effort
The French pharmaceutical company won’t proceed with the development of one of its experimental Covid-19 vaccines, saying it didn’t make sense to go forward in an already-crowded...
-
Sanofi reports positive interim results for its first mRNA COVID-19 vaccine candidate
Sanofi (SNY) announces positive interim results from a Phase 1/2 study of its mRNA-based COVID-19 vaccine candidate
-
Sanofi reports encouraging early results for COVID-19 mRNA vaccine candidate
Sanofi reports encouraging early results for COVID-19 mRNA vaccine candidate
-
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
Sanofi SA (NASDAQ: SNY) shares traded higher by 0.4% on Monday after the company scored an analyst upgrade. The Analyst: SVB Leerink analyst Geoffrey Porges upgraded Sanofi from Market...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
